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Randomized Trial of Cardiac Resynchronization in
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Asymptomatic Patients With Left Ventricular
Dysfunction and Previous Heart Failure Symptoms
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Martin St. John Sutton, MD,§ Stefano Ghio, MD,¶ Claude Daubert, MD, on behalf of the REVERSE
(REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group
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Pavia, Italy; and Rennes, France
Objectives We sought to determine the effects of cardiac resynchronization therapy (CRT) in New York Heart Association
(NYHA) functional class II heart failure (HF) and NYHA functional class I (American College of Cardiology/
American Heart Association stage C) patients with previous HF symptoms.
Background Cardiac resynchronization therapy improves left ventricular (LV) structure and function and clinical outcomes in
NYHA functional class III and IV HF with prolonged QRS.
Methods Six hundred ten patients with NYHA functional class I or II heart failure with a QRS 120 ms and a LV ejec-
tion fraction 40% received a CRT device (defibrillator) and were randomly assigned to active CRT (CRT-ON;
n  419) or control (CRT-OFF; n  191) for 12 months. The primary end point was the HF clinical composite
response, which scores patients as improved, unchanged, or worsened. The prospectively powered secondary
end point was LV end-systolic volume index. Hospitalization for worsening HF was evaluated in a prospective sec-
ondary analysis of health care use.
Results The HF clinical composite response end point, which compared only the percent worsened, indicated 16% wors-
ened in CRT-ON compared with 21% in CRT-OFF (p  0.10). Patients assigned to CRT-ON experienced a greater
improvement in LV end-systolic volume index (18.4  29.5 ml/m2 vs. 1.3  23.4 ml/m2, p  0.0001) and
other measures of LV remodeling. Time-to-first HF hospitalization was significantly delayed in CRT-ON (hazard
ratio: 0.47, p  0.03).
Conclusions The REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) trial demonstrates
that CRT, in combination with optimal medical therapy (defibrillator), reduces the risk for heart failure hospitaliza-
tion and improves ventricular structure and function in NYHA functional class II and NYHA functional class I (American
College of Cardiology/American Heart Association stage C) patients with previous HF symptoms. (REsynchronization
reVErses Remodeling in Systolic Left vEntricular Dysfunction [REVERSE]; NCT00271154). (J Am Coll Cardiol 2008;
52:1834–43) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.027f
(
f
f
M
r
a
D
Jardiac resynchronization therapy (CRT) with or without
n implantable cardioverter-defibrillator (ICD) improves
uality of life, functional status, exercise capacity, morbidity,
nd mortality in New York Heart Association (NYHA)
rom the *Department of Cardiology, Karolinska University Hospital, Stockholm,
weden; †Division of Cardiovascular Medicine and the Davis Heart and Lung
esearch Institute, Ohio State University, Columbus, Ohio; ‡Division of Cardi-
logy, Medical University of South Carolina, Charleston, South Carolina;
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania; ¶Poli-
linico San Matteo, Pavia, Italy; and the Département de Cardiologie, CHU,
ennes, France. Dr. Linde reports research grants, speaker honoraria, and consultingees from Medtronic and speaker honoraria and consulting fees from St. Jude
edical. Dr. Abraham reports research grants, speaker honoraria, and consulting aunctional class III and ambulatory class IV heart failure
HF) patients with left ventricular (LV) systolic dysfunction
See page 1844
ees from Medtronic, St. Jude Medical, and Biotronik. Dr. Gold reports consulting
ees from Medtronic and Boston Scientific and lecture fees and research grants from
edtronic, Boston Scientific, and St. Jude Medical. Dr. St. John Sutton reports
esearch grant support, speaker honoraria, and consulting fees from Medtronic as well
s research support from Paracore. Dr. Ghio reports consulting fees from Medtronic.
r. Daubert reports speaker honoraria and consulting fees from Medtronic and St.
ude Medical.
Manuscript received June 13, 2008; revised manuscript received July 31, 2008,
ccepted August 14, 2008.
a
t
t
m
s
s
t
o
a
z
d
i
h
M
P
l
(
c
(
e
w
(
m
r
s
o
l
b
c
n
p
a
h
o
w
S
c
t
w
C
1
2
v
r
t
I
p
r
O
a
C
i
a
c
t
p
T
w
p
i
t
a
h
i
i

t
e
6
w
b
p
n
fi
b
d
d
T
l
A
p
d
t
a
r
C
w
i
(
i
p
a
i
t
e
f
c
b
S
E
p
(
3
e
1835JACC Vol. 52, No. 23, 2008 Linde et al.
December 2, 2008:1834–43 Cardiac Resynchronization in Mild HFnd a prolonged QRS duration (1–5). Resynchronization
herapy also progressively improves LV structure and func-
ion in these patients (6), raising the possibility that CRT
ight delay disease progression in HF patients with less
evere symptoms through LV reverse remodeling. Two
mall studies in NYHA functional class II patients support
his hypothesis (7,8); however, both of these studies were
nly 6 months in duration and neither study included
symptomatic patients with systolic dysfunction.
We report the results of the REVERSE (REsynchroni-
ation reVErses Remodeling in Systolic left vEntricular
ysfunction) trial, a randomized, double-blind trial of CRT
n patients with asymptomatic and mildly symptomatic
eart failure and a prolonged QRS interval.
ethods
atient population. Eligible patients had American Col-
ege of Cardiology/American Heart Association Stage C
9), NYHA functional class I (previously symptomatic,
urrently asymptomatic) or NYHA functional class II
mildly symptomatic) HF for at least 3 months before
nrollment. Patients were required to be in sinus rhythm
ith QRS duration120 ms, to have a LV ejection fraction
EF) 40%, and to have a LV end-diastolic diameter 55
m as measured by echocardiography. All patients were
eceiving optimal medical therapy for HF (9,10), including
table doses of an angiotensin-converting enzyme inhibitor
r angiotensin II receptor blocker and a beta-blocker for at
east 3 months. Patients were excluded if in the 3 months
efore enrollment they were classified as NYHA functional
lass III or IV or had been hospitalized for HF. Those in
eed of cardiac pacing, those who had been paced from a
revious device, or those with permanent or persistent atrial
rrhythmias also were excluded. Other reasons for exclusion
ave been published previously (11). The ethics committee
f each center approved the protocol, and all patients gave
ritten informed consent.
tudy design and procedures. Patients meeting the entry
riteria underwent evaluations at baseline: NYHA func-
ional class, quality of life assessment (Minnesota Living
ith Heart Failure Questionnaire [12] and the Kansas City
ardiomyopathy Questionnaire [13]), 6-min walk test,
2-lead electrocardiogram (for QRS duration), and
-dimensional Doppler-flow echocardiography (to assess
entricular structure and function and the degree of mitral
egurgitation).
After baseline evaluation, patients underwent implanta-
ion of a CRT system (device and leads), with or without
CD capabilities. Within 21 days of informed consent,
atients who had undergone successful implantation were
andomly assigned in a 2:1 fashion to active CRT (CRT-
N) or to control (CRT-OFF) for 12 months. Thereafter,
ll patients were recommended to be programmed to
RT-ON, except in Europe, where patients were to remainn their assigned group for 24 months so that we could wssess the health economic out-
omes of early CRT interven-
ion. Randomization occurred in
ermuted blocks within centers.
hose assigned to CRT-ON
ere programmed to a mode that
aced both ventricles and inhib-
ted atrial pacing unless the in-
rinsic rate was 35 beats/min,
nd those assigned to CRT-OFF
ad the device programmed to
nhibit atrial or ventricular pac-
ng unless the intrinsic rate was
35 beats/min. The atrioven-
ricular delay was optimized by
chocardiography (11).
Patients were evaluated at 1, 3,
, and 12 months. During the randomized phase, patients
ere blinded to their randomization assignment and
linded personnel (heart failure staff who were managing
atients’ heart failure) administered quality of life question-
aires, patient global assessment, NYHA functional classi-
cation, 6-min walk test, and physical examination. Un-
linded personnel (i.e., electrophysiologist staff) performed
evice interrogation and programming, 12-lead electrocar-
iogram, echocardiography, and pacemaker follow up data.
he echocardiography recordings were evaluated by core
abs who were not informed of randomization assignments.
ll patients underwent a full echocardiogram at 12 months,
rogrammed to the CRT mode to which they were ran-
omized, followed by a limited echocardiogram with pa-
ients programmed in the opposite CRT mode. For those
ssigned to CRT-ON, a 10-min CRT washout period was
equired before obtaining the limited echocardiogram with
RT programmed off.
Investigators were asked to report all adverse events,
hich were classified for HF and system relatedness by an
ndependent Adverse Event Advisory/Endpoint Committee
AEAC) blinded to treatment modality. An unblinded
ndependent Data Monitoring Committee consisting of 3
hysician-scientists and a statistician reviewed accumulating
dverse events, hospitalization, and mortality data to mon-
tor for safety issues.
Crossover from the assigned mode was prohibited before
he 12-month assessment, except for patients assigned to
ither group who experienced chronic worsening of heart
ailure to NYHA functional class III or class IV. Such
rossovers required prior discussion between the responsible
linded site investigator and a member of the REVERSE
teering Committee and were allowed only as a last resort.
nd points and statistical analysis. The primary end
oint of the study was the HF clinical composite response
11,14). Using this end point, we classified patients into 1 of
response groups at 12 months after randomization: wors-
ned, unchanged, or improved. Patients were judged to be
Abbreviations
and Acronyms
AEAC  Adverse Event
Advisory/Endpoint
Committee
CRT  cardiac
resynchronization therapy
HF  heart failure
ICD  implantable
cardioverter-defibrillator
LV  left ventricular
LVESVI  left ventricular
end-systolic volume index
NYHA  New York Heart
Associationorsened if they died, were hospitalized (at any time during
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Cardiac Resynchronization in Mild HF December 2, 2008:1834–43he 12 months) because of or associated with worsening HF,
rossed over or permanently discontinued double-blind
reatment because of worsening HF at any time during the
2 months, demonstrated worsening in NYHA functional
lass at their 12-month visit, or reported moderately or
arkedly worse heart failure symptoms compared to before
RT implant (Patient Global Assessment) when asked at
he 12-month follow-up. Patients were judged to be im-
roved if they had not worsened and had demonstrated
mprovement in NYHA functional class at 12 months
nd/or reported moderately or markedly improved heart
ailure symptoms at the 12-month follow-up. Patients who
ere not worsened or improved were classified as un-
hanged. Hospitalizations and crossovers only contributed
o the end point if the AEAC verified their relatedness to
F. Because asymptomatic patients (NYHA functional
lass I) were included in the study and their NYHA status
ould not improve, the percent of patients worsened was
sed to compare the efficacy of CRT between study groups.
The left ventricular end-systolic volume index (LVESVI)
as the prospectively powered secondary end point. This
as measured as the absolute change between baseline and
2 months for comparison between the 2 randomized
roups. The 12-month echocardiographic measurements
ere made with CRT programmed off, irrespective of the
reatment assignment, with the same parameters in the full
chocardiographic protocol for CRT-OFF patients and a
imited echocardiographic protocol for CRT-ON patients.
n CRT-ON patients these measurements were recorded
fter a 10-min washout period. Two core laboratories for
chocardiography, 1 in the U.S. and 1 in Europe, performed
ll echocardiography measurements.
All end points were analyzed according to the intention-
o-treat principle; patients who crossed over were analyzed
n their original treatment assignment. All p values reported
re nominal, and all statistical tests are 2-sided. The study
ad a statistical power of 80% to detect an absolute
ifference of 12.1% in worsened HF clinical composite
esponses between the 2 groups with 512 randomized
atients. The study had 80% power to detect a difference of
.11 ml/m2 change in LVESVI between the 2 groups with
83 randomized patients. We used the larger of 512 and
83; therefore, the prespecified study sample size was 683
nrolled patients based on an assumed attrition rate of 25%
rom enrollment to randomization. For the pre-specified
nalysis of the primary end point, the percent of patients
orsened was used to compare the efficacy of CRT between
tudy groups with the chi-square test. Kaplan-Meier anal-
sis was used to analyze all-cause mortality and time to first
eart failure hospitalization. Time 0 was the date of ran-
omization and patients not experiencing an event were
ensored at 12 months. The log-rank test was used to assess
ignificance in both cases. Complication rates were com-
ared with the chi-square test. The difference in incidence
f ventricular arrhythmias was tested with the Comparison
f Incidence Rates (Large Sample Test) (15). Other sec- 0ndary end points were compared with the 2-sample t-test,
omparing the differences from baseline to 12 months (11).
or the HF clinical composite response (% worsened) odds
atio figure, 95% Wald confidence limits are reported.
nalyses were conducted with SAS software (version 9.1,
AS Institute, Cary, North Carolina). There were no
nterim analyses of the efficacy data and, therefore, the data
onitoring committee had no pre-specified stopping rules.
esults
tudy population. Patients were enrolled at 73 centers; 37
n the U.S., 1 in Canada, and 35 in Europe. Enrollment
egan in September 2004 and ended in September 2006. A
otal of 684 patients were enrolled in the study, with 648
ompleting a baseline assessment, 642 undergoing at-
empted CRT implant, and 621 being successfully im-
lanted. The average time from implant to randomization
as 4.8 days. Eleven of the 621 patients were not randomized
ecause of the following reasons: inclusion criteria not met,
omplete heart block, atrial arrhythmias, LV lead dislodgment,
oss of capture, death, heart failure status (n 2), and surgical
picardial LV lead use (n  3), leaving 419 randomized to
RT-ON and 191 randomized to CRT-OFF.
As previously described (16), baseline characteristics were
imilar in the 2 groups (Table 1). Almost all patients (97%)
ere on either an angiotensin-converting enzyme inhibitor
r an angiotensin receptor blocker and on a beta-blocker
95%). Thirty-five percent were receiving beta-blockers in
arget dose and 60% were receiving at least 50% of target
ose according to current HF guidelines (10). The mean
VEF was 26.7  7.0% and the mean LV end-diastolic
iameter was 66.9 8.9 mm. The mean QRS duration was
53  22 ms. A CRT-ICD was implanted in 83% of
uccessfully implanted patients and a CRT device in 17%,
ith no significant differences between randomization
roups on the basis of device type (Table 1). The overall
mplantation success rate was 97%.
ffects on primary and secondary end points. Of the 419
atients assigned to CRT-ON, 16% worsened in their HF
linical composite response at 1 year compared with 21% of
he 191 patients randomized to CRT-OFF (p 0.10) (Fig.
). The reasons for patients receiving a score of worsened,
mproved, or unchanged are listed in Table 2. Paired
VESVI data were available in 487 of 610 patients (80%).
he reasons for missing data were an unreadable echocar-
iogram at baseline (n  42) or 12 months (n  53),
chocardiographic examination not performed at baseline
n  3) or at the 12-month visit (n  14; 1 due to missing
ull echocardiogram, 10 due to missing limited echocardio-
rams, and 3 due to missing full and limited echocardio-
rams), and because of patient death before the 12-month
isit (n  11). The LVESVI improved (18.4  29.5
l/m2) in the CRT-ON group (n  324) compared with
he CRT-OFF group (1.3  23.4 ml/m2; n  163; p 
.0001) (Fig. 2). The observed reduction in LVESVI in
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roup (29.8 30.5 ml/m2; n 142) than in patients with
n ischemic etiology of HF (9.5  25.5 ml/m2; n  182),
ut was of similar magnitude in patients in NYHA func-
ional class I (15.4  27.6 ml/m2) and NYHA functional
lass II (19.1  30.0 ml/m2) HF. The difference in the
hange in LVESVI between CRT-ON and CRT-OFF was
tatistically significant in all the subgroups analyzed (Fig. 3).
ther measures of reverse remodeling also improved signif-
cantly with active CRT (Fig. 2). The interventricular
echanical delay was significantly reduced after 12 months
n CRT-ON compared with CRT-OFF (13.0  43.2 ms
n CRT-ON, n  276, vs. 0.2  34.0 ms in CRT-OFF, n
140; p  0.0007). The effect of CRT on the HF clinical
omposite response in various subgroups was evaluated (Fig.
) with the use of odds ratios. The overall odds ratio for the
tudy was 0.70 in favor of CRT-ON. The point estimates
or nearly all subgroups favored CRT-ON, demonstrating
onsistent results across the study population.
The change in the 6-min walk distance at 12 months
12.7  102.4 m in CRT-ON vs. 18.7  105.2 m in
RT-OFF; p  0.52) and quality of life by the Minnesota
N Groups
-OFF (n  191) CRT-ON (n  419) p Value
1.8 11.6 62.9 10.6 0.26
152 (80) 327 (78) 0.75
159 (83) 344 (82) 0.82
97 (51) 236 (56) 0.22
46 (24) 91 (22) 0.53
151 (79) 330 (79) 1.00
39 (20) 88 (21) 0.91
186 (97) 404 (96) 0.63
179 (94) 401 (96) 0.32
114 (60) 255 (61) 0.79
62 (32) 153 (37) 0.36
148 (77) 339 (81) 0.33
54 24 153 21 0.41
6.4 7.1 26.8 7.0 0.50
7.0 0.9 6.9 0.9 0.65
5.8 1.1 5.7 1.0 0.63
03 91 197 74 0.42
72 102 268 89 0.60
74 78 269 76 0.57
3.6 36.4 33.9 40.1 0.94
9.6 36.4 84.2 31.3 0.08
8.2 10.9 66.9 10.3 0.17
3.4 19.0 125.2 18.6 0.25
2.0 12.0 72.2 10.8 0.82
7.5 18.8 85.1 17.8 0.12
8.8 21.7 27.0 20.1 0.32
0.7 22.1 73.7 19.0 0.14
88 132 399 125 0.34
163 (85) 345 (82) 0.41
hronization therapy-implantable cardioverter-defibrillator; LV left ventricular; NYHA New YorkFigure 1 The Heart Failure Clinical Composite Response
The primary end point, comparing the proportion of worsened subjects at 12
months (p  0.10). CRT-OFF  control patients; CRT-ON  patients receiving
cardiac resynchronization therapy.atient Baseline Characteristics in the CRT-OFF and CRT-ON Groups
Table 1 Patient Baseline Characteristics in the CRT-OFF and CRT-O
Parameter CRT
Age, yrs 6
Gender, male (%)
NYHA functional class II, n (%)
Ischemic, n (%)
Diabetic, n (%)
ACE inhibitors, n (%)
ARBs, n (%)
ACE inhibitors or ARBs, n (%)
Beta-blockers, n (%)
At least 50% of target dose of beta-blockers, n (%)
100% of target dose of beta-blockers, n (%)
Diuretics, n (%)
Intrinsic QRS width, ms 1
LV ejection fraction, % 2
LV end-diastolic dimension, cm
LV end-systolic dimension, cm
LV end-systolic volume, cm3 2
LV end-diastolic volume, cm3 2
LV mass, g 2
Interventricular mechanical delay, ms 3
Glomerular filtration rate, ml/min 8
Heart rate, beats/min 6
Supine systolic blood pressure, mm Hg 12
Supine diastolic blood pressure, mm Hg 7
Weight, kg 8
Minnesota Living With Heart Failure Score 2
Kansas City Cardiomyopathy Questionnaire Overall Summary Score 7
6-min hall walk, m 3
CRT-ICD implanted, n (%)
values are 2-sided and were calculated with the Fisher exact test or the 2-sample t-test.core (8.4  17.1 in CRT-ON vs. 6.7  15.9 in
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Cardiac Resynchronization in Mild HF December 2, 2008:1834–43RT-OFF; p  0.26) and the Kansas City score (8.7 
7.8 in CRT-ON vs. 8.5  16.1 in CRT-OFF, p  0.91)
id not improve with CRT. There were 196 adjudicated
pisodes of ventricular tachycardia or ventricular fibrillation
0.57 per year in 54 of 345 CRT-ICD patients) in
RT-ON and 114 episodes (0.70 per year in 24 of 163
RT-ICD patients) in CRT-OFF (p  0.09 favoring
RT-ON).
There were 222 hospitalizations during the 12-month
ollow-up period. There were 17 HF-related hospitaliza-
ions in the CRT-ON group (n  419) and 15 in the
RT-OFF group (n  191). The time-to-first HF hospi-
alization was significantly delayed in the CRT-ON group
hazard ratio: 0.47, p 0.03) (Fig. 5). There were 12 deaths
rom the time of randomization through the 1-year follow
p. The mortality rate was 2.2% at 12 months for the
Figure 2 Mean LVESVI, LVEDVI, and LVEF at Baseline and 12 M
Error bars represent 95% confidence intervals. Red circles  CRT-OFF (n  163);
LVEDVI  left ventricular end-diastolic volume index; LVEF  left ventricular ejectio
in Figure 1.
F Clinical Composite Response Details in the CRT-OFF and CRT-O
Table 2 HF Clinical Composite Response Details in the CRT-OF
Clinical Composite Response Detail
Worsened, n (%)
Death
Hospitalization due to or associated with worsening HF
Crossover due to worsening HF
Worsened patient global assessment and NYHA functional class
Worsened NYHA functional class only
Worsened patient global assessment only
Improved, n (%)
Improved on patient global assessment and NYHA functional class
Improved NYHA functional class only
Improved patient global assessment only
Unchanged
ata in the table are listed in hierarchical order (subjects are included only in one subcategory.
HF  heart failure; other abbreviations as in Table 1.RT-ON group and 1.6% for the CRT-OFF group (p 
.63). Deaths were adjudicated to be due to progressive HF
n  3), documented arrhythmias (n  2), gastrointestinal
leeding, renal cancer, aspiration pneumonia, pulmonary
brosis, and electromechanical dissociation. No cause was
ble to be determined for 2 deaths. Nine of the deaths were
ot related to the therapy, procedure, or system and such
elatedness was unknown for 3 deaths.
omplications. An adverse event that resulted in inva-
ive intervention or the termination of significant device
unction regardless of other treatments was classified as a
omplication. During or just before implantation there
ere 26 procedure or system-related complications
mong the 642 patients (i.e., the perioperative complica-
ion rate was 4%) who underwent an implant attempt,
ncluding adverse drug reaction (n  4), pneumothorax
s in the CRT-OFF and CRT-ON Groups
triangles  CRT-ON (n  324). CRT  cardiac resynchronization therapy;
tion; LVESVI  left ventricular end-systolic volume index; other abbreviations as
ups
CRT-ON Groups
CRT-OFF (n  191) CRT-ON (n  419)
41 (21) 67 (16)
3 (2) 9 (2)
14 (7) 12 (3)
5 (3) 1 (1)
0 (0) 2 (1)
18 (9) 40 (10)
1 (1) 3 (1)
76 (40) 228 (54)
11 (6) 69 (16)
28 (15) 59 (14)
37 (19) 100 (24)
74 (39) 124 (30)onth
green
n fracN Gro
F and
(
s
v
2
1
(
T
2
1
t
t
r
e
O
(
p
v
n
d
o
h
t
1839JACC Vol. 52, No. 23, 2008 Linde et al.
December 2, 2008:1834–43 Cardiac Resynchronization in Mild HFn  4), atrial fibrillation or flutter (n  4), coronary
inus dissection (n  3), pulmonary edema (n  2),
entricular fibrillation (n  2), complete heart block (n 
), cardiac tamponade (n  1), pericardial effusion (n 
), electromechanical dissociation (n  1), hypotension
n  1), and increased defibrillation threshold (n  1).
wenty-five of the 26 complications were resolved within
8 days of onset.
After implantation and during the 12-month follow-up,
01 of the 621 successfully implanted patients experienced a
otal of 138 procedure or system-related complications (i.e.,
Figure 3 Effect of CRT on LVESVI
An analysis of the mean change in LVESVI (ml/m2) from baseline to 12 months is
confidence interval, is shown for each subgroup. Confidence intervals that do not
blood pressure, ejection fraction, end-systolic volume index, QRS width, interventri
median value in the study sample. Green bars  CRT-ON; red bars  CRT-OFF. IC
NYHA  New York Heart Association; other abbreviations as in Figure 2.he post-operative procedure or system-related complication cate was 16%). There was no statistically significant differ-
nce in complication rates between CRT-ON and CRT-
FF patients during the first 12 months of randomization
p  0.64). Of the 138 complications, the most common
ostimplant complications were lead dislodgements (left
entricular n  41, right ventricular n  15, and right atrial
 10), inappropriate device irritation of tissue (e.g.,
iaphragmatic nerve stimulation, n  14), atrial fibrillation
r flutter (n  8), implant site hematoma (n  5),
ypotension (n  4), and pericardial effusion (n  4). At
he time of database closure, 128 (93%) of post-implant
. The difference (CRT-OFF – CRT-ON) in the mean changes, along with its 95%
0 indicate statistical significance (p  0.05). The subgroups of age, systolic
echanical delay, and glomerular filtration rate are divided according to the
plantable cardioverter-defibrillator; IVMD  interventricular mechanical delay;shown
include
cular m
D  imomplications were resolved (66% within 3 weeks of onset),
7
e
p
r
i
t
a
t
w
t
t
r
r
r
t
t
r
4
v
c
e
C
f
p
f
n
C
d
1840 Linde et al. JACC Vol. 52, No. 23, 2008
Cardiac Resynchronization in Mild HF December 2, 2008:1834–43were ongoing, 2 were unresolved with no further actions
xpected, and one resulted in death.
Because the majority of REVERSE patients were im-
lanted with CRT-ICD devices, the primary incremental
isk for CRT or CRT-ICD therapy over ICD therapy alone
s the LV lead and CRT therapy. That is, because most of
hese patients had a clinical indication for ICD therapy (17)
nd were to be subjected to the risks of ICD implantation,
he incremental risk of LV lead implantation and CRT itself
as analyzed. Among the 621 successfully implanted pa-
ients during the first 12 months, there was one CRT
herapy-related complication in which cardiac failure was
esolved by turning CRT off. There were 66 LV lead-
elated complications among 59 patients (i.e., the LV lead
Figure 4 Effect of CRT on the Heart Failure Clinical Composite
Analysis of the percentage worsened in the heart failure clinical composite response u
An odds ratio of 0.5 means the odds of a patient being in worsened condition are
tolic blood pressure, ejection fraction, end-systolic volume index, QRS width, interv
median value in the study sample. Because of missing baseline data, not all subgelated complication rate was 10%) which required reopera- fiion in 48 patients (8% of successfully implanted pa-
ients). The most common events in the 66 LV lead
elated complications were LV lead dislodgements (n 
1), diaphragmatic stimulation (n  14), and subclavian
ein thrombosis (n  3). In 86% of cases, these LV lead
omplications were resolved without untoward clinical
ffects.
rossovers and patient compliance. The 12-month
ollow-up was completed by 594 of the surviving 598
atients (99%). No randomized patients were lost to
ollow-up or exited from the study. There were 20 perma-
ent crossovers in 12 months. Six patients crossed over from
RT-ON to CRT-OFF due to worsening HF (n  2),
iaphragmatic nerve stimulation (n  2), persistent atrial
onse of Worsened in Subgroups
dds ratios and 95% confidence intervals is shown. Lower odds ratios favor CRT-ON.
s high in the CRT-ON group as the CRT-OFF group. The subgroups of age, sys-
ular mechanical delay, and glomerular filtration rate are divided according to the
umbers equal a total of 610. Abbreviations as in Figures 1, 2, and 3.Resp
sing o
half a
entric
roup nbrillation (n  1), and incorrect programming (n  1).
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RT-ON due to worsening HF (n  12), patient unwill-
ngness to remain in the assigned mode (n  1), and
nadvertent erroneous programming (n  1). Of the 14
rossovers investigators indicated were due to worsening
F, the AEAC adjudicated 13 as being due to HF. Of
hese, 6 patients received a worsened score in the HF
linical composite as a result of the crossover (Table 2); the
thers were hospitalized for HF before their crossover.
iscussion
he REVERSE trial shows for the first time in a large
ulticenter, randomized, double-blind study that CRT
mproves ventricular structure and function in patients with
symptomatic and mildly symptomatic heart failure. In
ontrast, the percent worsened in the composite primary
nd point compared with the percent unchanged or im-
roved did not differ significantly. In addition, REVERSE
emonstrates a significant reduction in HF morbidity de-
ned as the need for hospitalization for worsening HF.
pecifically, there was a statistically significant 53% relative
isk reduction in time to first HF hospitalization associated
ith active CRT. Finally, REVERSE found no significant
mprovement in quality of life or exercise capacity with
RT. This latter finding is not surprising in a group of
atients with little functional impairment at baseline.
The primary end point was chosen because it combines
he occurrence of major events such as HF morbidity, HF
ospitalization, and mortality with NYHA functional class
nd quality of life (14). It was thought to be more sensitive
Figure 5 Time to First Heart Failure Hospitalization in the
First 12 Months in the CRT-OFF and CRT-ON Groups
Heart failure (HF) relatedness of hospitalizations was adjudicated by the
Adverse Events Advisory Committee. The number at risk at 12 months repre-
sents the number of patients who had a randomized follow-up after 365 days
and had not experienced an HF hospitalization. The number decreases at 12
months mainly because U.S. subjects finished randomized follow-up at 12
months. Abbreviations as in Figures 1 and 2.han conventional approaches in detecting the presence or bbsence of a true treatment effect in CRT studies. Because
he clinical event rate was expected to be lower in the
EVERSE patient group than in moderate-to-severe HF
atients, the composite was expected to be more sensitive
han any of its individual parameters per se to detect a
reatment difference by CRT. In previous studies in which
uthors used the clinical composite HF end point (14), the
istribution of “worsened,” “unchanged,” and “improved”
as compared. We used the clinical composite to assess
hanges in less symptomatic and even asymptomatic pa-
ients. Hence, we regarded both “unchanged” and “im-
roved” as lack of disease progression and “worsened” as
isease progress. Therefore, we analyzed the percent wors-
ned as our primary end point. When this prespecified
nalysis plan was used, the study did not meet its primary
nd point (14). Nonetheless, the extent of reverse structural
nd functional remodeling in the present study was compa-
able with that of previous CRT studies in NYHA func-
ional class III and class IV patients (2,4,5).
Importantly, more patients in the REVERSE trial than
n these trials were on beta-blockers for at least 3 months
efore consent and, to a larger extent, at the target dose with
o dose alterations allowed during the randomization phase
nless medically necessary. This result suggests that CRT
roduces significant additive effects on ventricular remodel-
ng that occur in addition to HF drug therapy. Reverse
emodeling by CRT has previously been reported in smaller
tudies of NYHA functional class II HF patients with 6
onths of follow-up (7,8). Thus, REVERSE extends these
bservations in a larger number of patients with more
rolonged follow-up. This finding, along with the observa-
ion that reverse LV remodeling but not symptomatic
mprovement has been linked to better survival in another
RT study of 141 patients followed for 695 days (18),
upports the improvement in clinical outcomes observed in
EVERSE. It is possible that the 12-month observation
eriod was too short to meet the clinical composite end
oint in the mildly symptomatic or asymptomatic patients
n REVERSE. The 24-month study period in the Euro-
ean cohort may have important implications for other
RT studies in this population.
Overall, the mortality and hospitalization rates were low
n the REVERSE trial. This is not surprising because the
EVERSE patient population had asymptomatic or mildly
ymptomatic HF, which is known to be associated with low
ates of morbidity and mortality (19). Moreover, RE-
ERSE patients were younger, had a more narrow QRS
idth, and had greater adherence to present pharmacolog-
cal HF guidelines at baseline than in most previous trials.
onetheless, a clear clinical benefit on time to first HF
ospitalization was found in association with active CRT in
he present study. Although REVERSE was not designed
s a morbidity and mortality trial, this observation could
uggest that CRT in NYHA functional class I and II
atients over a longer treatment period could provide
enefits in morbidity and even in mortality. In the CARE
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YHA functional class III to IV patients, incremental
enefits in mortality and cardiovascular hospitalizations
ere shown with a mean follow up period of 36 months by
RT, which was also demonstrated within the mildest
ubgroup (20,21). It remains to be demonstrated if this is
rue also in NYHA functional class I to II patients. The
ong-term effect of CRT on mortality and HF events is
urrently being investigated in the RAFT (Rythmol Atrial
ibrillation Trial) (22) and MADIT CRT (Multicenter
utomatic Defibrillator Implantation Trial with Cardiac
esynchronization Therapy) (23) studies.
The benefits of CRT in the REVERSE patient popula-
ion must be balanced against the risks. Because most
atients in REVERSE had a primary preventive indication
or an ICD (17), the added risk of implanting a CRT device
s related to the LV lead. This risk was relatively low with a
V lead related complication rate of 10% over the 12
onths of follow-up. The reoperation rate for LV lead-
elated complications was similar in the REVERSE trial
8%) to the CARE HF trial, where LV-lead related major
dverse events prompted reoperations in nearly 7% of
atients (24). The complication rate will be further assessed
n the 24-month randomization period in the European
ohort as it will be for the full 5-year follow up for all
EVERSE patients. The 97% implant success rate was very
igh, representing an improvement in implantation tech-
ique and lead technologies compared with earlier CRT
tudies (2,3).
onclusions
e found that CRT reduces the risk for HF hospitalization
nd reverses LV remodeling over 12 months in patients with
merican College of Cardiology/American Heart Associa-
ion Stage C, NYHA functional class I and Class II HF,
aising the possibility that CRT might delay disease pro-
ression in HF patients with less severe symptoms through
V reverse remodeling.
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APPENDIX
or a list of the 73 centers who contributed
o this study, please see the online version of this article.
